Copyright © 2021. Inderes Oyj. All rights reserved.

Optomed

Analyytikko

Yhtiön vuosikertomukset

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
14.7.
2021

Redeye revises slightly its revenue and EBITDA projections for 2021. While we remain conservative in our near-term expectations, we maintain our conviction that Optomed is on the path of spectacular growth.

Muut analyysit
11.5.
2021

Redeye sees one more sign for sales growth for Optomed with the market authorization for the Aurora camera in Brazil.

Muut analyysit
6.5.
2021

Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.

Muut analyysit
12.4.
2021

Redeye raises the fair value of Optomed to EUR 13 per share, a new bull case of EUR 17 per share and a bear case of EUR 5. As we expected, the trend for "remote-everything" favours Optomed. We believe this transformation will continue and even accelerate in the coming years and see Optomed as positioned for strong growth with both superior technology and solid execution capability.

Optomed

ipo 

Yhtiöllä seuraavat leimat

Inderes Yhtiöasiakas